ASA and NSAIDs with Melagatran/Ximelagatran or Enoxaparin Do NOT Increase Bleeding in Patients Undergoing Joint Replacement Surgery. The METHRO III Study
Abstract number: P1627
Dahl1 O, Eriksson2 B, Agnelli3 G, Cohen4 A, Mouret5 P, Rosencher6 N, Bylock7 A, Panfilov7 S, Andersson7 M, Ögren7 M
11Thrombosis Research Institute, London, UK 22Sahlgrenska University Hospital/Östra, Göteborg, Sweden 33University of Perugia, Perugia, Italy 44Guy's, King's, and St Thomas' School of Medicine, London, UK 55Frankfurt-Höchst Clinic, Frankfurt, Germany 66Paris M5 University and Cochin Hospital, Paris, France 77AstraZeneca R&D Mölndal, Mölndal, Sweden
Concomitant use of anti-inflammatory drugs and anticoagulants may raise concerns about bleeding in relation to surgery. Melagatran/ximelagatran has been approved as thromboprophylaxis in orthopaedic surgery, to be initiated 48 h after surgery. ASA <0.5 g/d and NSAIDs with t1/2 <20 h were allowed in the trials. A post-hoc analysis of the METHRO III study was undertaken to find out if this combination increased bleeding. Patients were randomized to either sc melagatran 3 mg started 412 h after surgery followed by oral ximelagatran 24 mg bid, or sc enoxaparin 40 mg daily started the evening before surgery. Treatment duration was 811 days. Analyses were performed based on first dose of melagatran administered 48 h and 812 h post-surgery. Data for the 48 h post-surgery group are presented in the table. Similar results were seen in the 812 h post-surgery group and the overall 412 h post-surgery population.
Conclusion: ASA and NSAIDs in addition to melagatran or enoxaparin did not increase bleeding in patients undergoing joint replacement surgery.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2005; Volume 3, Supplement 1: abstract number
|Session name:||XXIst ISTH Congress|
|Subject:||Poster Session Wednesday|
|Back to top|